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Abstract 
 
 
 
 
 
 
 
The use of therapeutic mAbs as the anti-TNFa agents has been known not to cure, but 
treat auto-immune diseases  such as the inflammatory bowel diseases (IBD), improving 
the overall quality of life of patients. These therapeutic mAbs are characterized by their 
high specificity allowing to block therapeutic targets as pro-inflammatory cytokines such 
as TNFa. However, as mAbs are biological drugs, called proteins. Their fundamental 
disadvantage is the risk of inducing immunogenicity, which can affect the effectiveness 
and safety of the drug, leading to loss of therapeutic response in patients. This 
phenomenon is called LoR. For that reason, it is necessary to monitor the treatment of 
these drugs, also referred to as TDM. Developing therapeutic mAbs is a complex and 
expensive process due to the complexity of the protein molecular structure. It requires 
carefully production, storage and quality control, which reflects to their high cost. Since the 
patent of therapeutic mAbs has expired, many manufacturers have taken the opportunity 
to introduce biosimilar drugs to the market. This has allowed for national health systems to 
spend less resources, making it accessible to more patients. 
CT-P13 was the first biosimilar drug of Infliximab to be approved by EMA in 2013, after 
the drug showed similar effectiveness and safety in rheumatoid arthritis and ankylosing 
spondylitis patients in two main studies called PLANETRA and PLANETRAS. Based on 
the results obtained in these studies the therapeutic indication of CT-P13 was 
extrapolated to the IBD in 2014 which leads to some mistrust in relation of the efficacy and 
safety of biosimilar in IBD patients.  
Doubts of extrapolation seem to be a non-issue nowadays since the post-commercialize 
studies attest to the similarity of CT-P13 face to the original drug. However, doubts 
relating to switching, multiple-switching, reverse-switching and cross-switching still persist. 
To evaluate if these drugs are similar, a comparison is done of drug and other levels and 
ADAs. The ELISA essays have been widely used and stand out due to it’s simplicity.To 
measure a patients ADAs level bELISA, which is a type of ELISA can be used, even 
though bELISA has it’s limitations. The presence of drug and IgG4 subtype ADAs are 
described as being factors that difficult the ADAs detection which makes with the same 
detection depending on the sensibility of each commercial kit, although these differences 
may not be significant. 
The aim of this study is to evaluate immunogenic response in patients treated with 
biosimilar CT-P13 through the detection of the drug and CT-P13 in order to verify how the 
presence of ADAs interferes with pharmacokinetics. Mapping epitopes of biosimilar and 
anti-Remicade ADAs with resource to an in house ELISA study, can verify which drugs 
are most immunogenic between IBD patients.  
 
 
Another in house ELISA study was done in order to map epitopes of anti-biosimilar and 
anti-Remicade ADAs subtype IgG4. Ultimately, a neutralization study was done to detect 
the presence of neutralizing antibodies (NADAs). 
In general, the data presented in this study suggests that CT-P13 and Remicade are 
similar in inducing an immune response in IBD patients, corroborating with others studies 
described. Therefore the switching between Remicade and biosimilar should not be 
motive of mistrust in terms of effectiveness and safety. 
Key words: ADAs, CT-P13, Immunogenicity, NADAs, TDM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Resumo 
 
 
 
 
 
 
 
O uso de mAbs terapêuticos tais como os agentes anti-TNFa têm permitido, não curar 
mas sim tratar, doenças auto-imunes como as doenças inflamatórias intestinais (DII), 
melhorando assim a qualidade de vida dos doentes que as vivenciam. Estes mAbs 
terapêuticos caracterizam-se pela sua alta especificidade permitindo bloquear alvos 
terapêuticos como citocinas pró-inflamatórias tais como o TNFa. Porém os mAbs 
terapêuticos uma vez tratando-se de medicamentos biológicos, nomeadamente 
proteínas, têm como fundamental desvantagem poder induzir nos doentes 
imunogenicidade que pode afectar a eficácia e a segurança destes fazendo com que os 
doentes deixem de responder à terapêutica, fenómeno designado por LoR que torna 
necessário a monitorização da terapêutica destes fármacos designada por TDM. 
Desenvolver mAbs terapêuticos é um processo complexo e dispendioso devido à 
complexidade da estrutura molecular das proteínas que requer cuidados na produção, 
armazenamento e controlo de qualidade o que se reflecte no seu custo elevado. A queda 
das patentes dos mAbs terapêuticos deu oportunidade à introdução de medicamentos 
biosimilares no mercado que por não terem de ser submetidos a todos os estudos a que 
os originais tiveram de ser sujeitos, são mais económicos permitindo que os sistemas 
nacionais de saúde possam economizar verba e com que mais doentes possam usufruir 
da terapêutica. 
O CT-P13 foi o primeiro biosimilar do Infliximab original a ser aprovado pela EMA em 
2013 após o fármaco ter demonstrado eficácia e segurança similares nos doentes com 
atreite reumatóide e espondilite anquilosante em dois estudos principais denominados de 
PLANETRA e PLANETRAS. Com base nos resultados obtidos nestes estudos a 
indicação terapêutica do CT-P13 foi extrapolada para a DII em 2014, o que levantou 
alguma desconfiança em relação à eficácia e segurança do biosimilar nos doentes com 
DII. A questão da extrapolação parece estar ultrapassada nos dias que decorrem uma 
vez que estudos de pós comercialização atestam a similaridade do CT-P13 face ao 
produto de referência. Porém dúvidas persistem em relação à substituição (switching), 
múltiplo-switching, o switching -reverso e switching-cruzado.  
A avaliação da similaridade destes fármacos tem sido efectuada por medição do perfil de 
fármaco e de anticorpos antifármaco (ADAs). Para medir estes parâmetros destacam-se 
os ensaios de ELISA que têm sido vastamente utilizados devido à simplicidade de 
execução desse tipo de ensaio. Na medição de ADAs pode ser salientado bELISA, 
contudo está documentado algumas limitações deste tipo de ensaio na detecção de 
ADAs. A presença de fármaco e de ADAs do subtipo IgG4 estão descritas como sendo 
factores que dificultam a detecção de ADAs o que faz com que essa mesma detecção 
dependa da sensibilidade de cada kit comercial embora as diferenças possam não ser 
significativas.  
O objectivo deste estudo foi avaliar a resposta imunogénica dos doentes tratados com o 
biosimilar CT-13 pela detecção de fármaco e de CT-P13 a fim de verificar como a 
presença de ADAs interfere com a farmacocinética. Mapear os epitopos dos ADAs anti-
biosimilar e anti-Remicade com recurso a um ensaio de ELISA in house, de modo a 
verificar qual dos fármacos é mais imunogénico entre os doentes com DII, sendo que à 
parte foi optimizado e realizado outro ELISA in house no sentido de mapear epitopos de 
anti biosimilar e anti Remicade ADAs do subtipo IgG4. Por último realizou-se um ensaio 
de neutralização para deteção da presença de anticorpos neutralizantes (NADAs). 
 
 
No geral os dados apresentados neste trabalho sugerem que o CT-P13 e Remicade são 
similares na resposta imune que induzem nos doentes com DII o que corrobora com 
outros estudos descritos. Assim sendo assim o switching entre o Remicade e o biosimilar 
não deverá ser motivo de desconfiança em termos de segurança e efectividade.  
Palavras-chave: ADAs CT-P13, Immunogenicidade, NADAs, TDM. 
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1.1 Biologic medicines 
Biologic medicines also designated biopharmaceuticals are a class of medicines 
obtained by living organisms. These kinds of medicines are polymers of amino acids 
protein molecules that include protein molecules or peptides. How proteins are huge 
macromolecules are more difficult to characterize comparatively with the general of 
chemical drugs (Berghout, 2011; Peres, Padilha & Quental, 2012). Due to the complexity 
of the tri-dimensional protein structure small differences can occur during the production 
process because the cell lines that generate the protein of interest are prone to generate 
variations in protein products which can influence their quality, efficacy and safety. These 
variations can be present in every new batch that is produced, and so, a major control of 
quality, efficacy and safety is necessary which makes these medicines more difficult to 
develop, justifying their high prices (de Mora & Fauser, 2017; Mulcahy, Hlavka & Case, 
2018). The first generation of biologics was launched in the late 1970s and early 1980s, 
and this class of drugs is today one of the high growing sectors of the pharmaceutical 
industry (Gabbani, Deiana, Annese; 2017). The great success of the biologic medicines is 
because these class of drugs  are designed to block specific pathways of action of some 
disease, so they are more specific and selective compared with conventional drugs and 
this can be considerable an advantage. Some examples of these drugs are vaccines, 
blood components, allergenics, somatic cells, gene therapy, tissues and recombinant 
therapeutic proteins (Kennedy, Oliveira , Granja, Sacramento,  2018). About the 
recombinant therapeutic proteins, these treatments has the disadvantage to be prone to 
provoke intolerable immune response in some patients that recognize the biologic agent 
as a strange molecule to the organism, and so generating anti-drug antibodies (ADAs) 
that can affect the efficacy of the biologic drug and also development of side effects can 
occur.  The mechanism whereby biologic protein drugs have the ability to induce an 
immune response mediated by ADAs is named immunogenicity and it can manifests with 
different intensities once it is a result of multifactorial consequences such as genetic 
background, severity of the disease that the biologic are design to treat, routine of 
administration, condition of the drug that comprehends aggregation and denaturation of 
the therapeutic protein which could have a significant impact on efficacy and safety of 
biological therapies as well (Dingermann, 2008). 
 
1.2 Therapeutic mAbs 
Some biologic medicines are monoclonal antibodies (mAbs) that are Abs produced by 
unique B-cell lymphocyte which produce only one antibody (Ab) type that have equivalent 
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biological and physicochemical proprieties and so that a same affinity and avidity and they 
bind to only one epitope on the antigen (Dingermann, 2008). MAbs where firstly obtained 
by the hybridom technic developed by Geores Köhler and Cesar Milstein in 1975. The 
technic consist in the production of a hybridom cell by the fusion between a lymphocyte B 
cell from a mouse pre induced to generate an immune response against the antigen of 
interested with a myeloma that is a kind of cancer cell. From these fusion results a hybrid 
immortalized cell line named hybridoma that produce mAbs. The greatness of the mAbs 
achievement was that contrary to the polyclonal Abs that are generated against different 
epitopes of the same antigen, mAbs once are generated only to the same epitope are 
much more specific. The exploration of mAbs specificity was a big step for the application 
of mAbs as therapeutic drugs. Nowadays mAbs are obtained with resource to 
biotechnology process such as recombinant DNA, protein engineering or phage display. 
After all mAbs obtainment opened new doors to the immunology science progress (Martin 
& Bugelski, 2012). Their application allowed the development or enhanced of assays such 
as radioimmunoassay, enzymatic immune assay (EIA) or flow-cytometry based on 
specific mAbs conjugated to fluorophores and so that, more specifics.  This improvement 
became easier the identification of biomarkers, cell population and cell path ways. 
Therefore mAbs are antibodies which are glycosylated proteins with “Y-shape” composed 
by two heavy chains (CH) and two light chains (CL). Abs also has a constant fragment 
(FC) and a variable fragment (FV). The variable portion of the light chain (VL) can be 
kappa (K) or lambda (λ) type depending of some differences in polypeptide sequence. 
What codify if an antibody displays a K or a λ chain are two rearranged DNA sequences 
(VJ) while the variable regions of the CH are codified by three rearranged DNA sequences 
(VDJ). Farther each variable region contains three hypervariable sub-regions designed 
complementary determining regions (CDR1, CDR2 and CDR3) that form the paratope that 
means the antigen biding site which hold the epitope region on the antigen. An antibody 
Ab is composed by four chains held together by disulfide bounds. About these four chains, 
two of them are identical light chains with a mass about 22 KDa each and the other two 
are identical heavy chains with a mass about 53 KDa (Arosa, Cardoso, & Pacheco, 2012). 
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Figure 1 - Antibody structure.  
Representation of an immunoglobulin structure. In dark blue is represented the constant regions of the heavy 
chains (CH1, CH2, CH3). The clear blue represents the variable region of the heavy chain (VH). The dark 
green is the constant region of the light chain (CL) and the clear green the variable region of the light chain 
(VL). In orange is represented the paratopes with their complementarity-determining region (CDRs) and the 
yellow represents the antigen.  
Source: Novimmune -- Science: Antibodies. (2016). Novimmune.com. Retrieved 26 October 2016, from 
http://www.novimmune.com/science/antibodies.html 
 
There are 5 classes of Abs (IgA, IgD, IgG, IgE and IgM) according to the type of Fc 
region. IgA has alpha (α) Fc region, IgD has delta (δ) Fc, IgG has gama (γ) Fc, IgE has 
epsilon (ε) Fc and finally IgM takes mu (µ) Fc. Further the Abs have kappa (k) or lambda 
(λ) light chains.  IgGs are the Ig which perform more activity in the immune system. They 
have a mass of about 150 KDa and are the main Igs in the blood stream and lymph. The 
half-life of 23 days which is the major among all five Abs classes, form 15% of total serum 
proteins and exist in the blood as a monomer. Further there are different isotypes of IgGs. 
IgG1, IgG2a, IgG2b, IgG3 and IgG4. IgGs and have functions like opsonization and 
agglutination that are important to facilitate the phagocytosis process by macrophages 
because macrophages express Fc receptors (FcR) which links to the Fc portion of IgG, on 
the other hand the Fab region links to specific regions on the antigens in bacteria or other 
pathogens named epitopes. Another efficiency of IgGs are the activation of the 
complement system, neutralization of toxins and virus and the opsonization of damage 
cells promoting the connection with the NK cells that also express FcR and thus 
contributing to the elimination of damaged cells by cytotoxicity (Arosa et al, 2012). 
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Figure 2 -  IgGs Subclasses 
The different subtypes of IgG antibodies that vary depending of the number of disulfide bounds in the hinge 
region and also of their amino acid sequence. IgG1) Immunoglobulin 1. IgG2) Immunoglobulin 2. IgG3) 
Immunoglobulin 3. IgG4) Immunoglobulin 4. 
Source: Owen, Punt, Stranford, Jones, & Kuby, 2013. Kuby immunology (p. 89). New York: W.H. Freeman 
 
1.3 Type of mAbs 
The mAbs can be classified as mouse, chimeric, humanized and human 
depending of the percentage of murine and human sequences and that determines the 
mAb name. Theoretically the mAb type can have impact on immunogenicity, once murine 
mAbs are expected to be more immunogenic then chimeric mAbs, and chimeric mAbs 
more immunogenic then humanized that finally is supposed to be more immunogenic then 
full human mAbs although the idea that full human mAbs are non-immunogenic is wrong 
because even full human mAbs have the ability to induce immunogenicity. By the other 
hand chimeric mAbs are well tolerated among some patients. Is important to have in mind 
that the answer how human the mAb is or how murine the mAb is, is just one of the 
different aspects that influence immunogenicity, however there are other aspects that 
influence immunogenicity as previously mentioned that also can have impact (Atzeni et al, 
2013). 
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Figure 3 - Schematic representation and nomenclature of mAbs in clinical use in IBD. 
The figure represents the therapeutic mAbs nomenclature, regarding to humanization level.   
Source: Adapted from Lee, Chinen, & Kavanaugh, 2010. Immunomodulator therapy: monoclonal antibodies, 
fusion proteins, cytokines, and immunoglobulins. Journal of Allergy and Clinical Immunology, 125(2), S314-
S323. 
 
1.4 Pharmacokinetics of therapeutic mAbs 
Therapeutic mAbs are proteins and needs to be administrated by intravenous or 
subcutaneous infusions. Once these drugs are used to treat chronic conditions in general, 
multiple infusions are needed to achieve the remission of symptoms and to maintain the 
diseases under control. Multiple infusion regimes implies that physicians have to establish 
a right dosage and a right interval of drug administration, for each patients and at the 
beginning of the treatment some changings in these two parameters could be necessary 
until the steady state (ss) be achieved.  Due to the multiple infusions the pharmacokinetics 
of therapeutic mAbs fits with the bolus graphic (Brandse et al, 2017). 
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Figure 4 - Pharmacokinetic of multiple infusions of therapeutic mAbs 
Represent the infliximab pharmacokinetic of multiple infusions bolus graph. Concentration of IFX at the steady state (Css), 
maximum serum concentration (Cmax), minimum serum concentration (Cmin), area under the curve (AUC), trough levels 
(TL).  
Source: Adapted from Maini et al, 1999; Yoo et al, 2013. 
 
 
To reach the steady state the physician should evaluate the area under the curve 
(AUC) of the continues infusions and when the multiple infusions start showing a similar 
AUC geometry and also showing same values of minimums concentration (Cmin) 
(Brandse et al, 2017). 
 
1.5 Biosimilars 
When the patents of conventional drugs expired, generic copies of their reference 
products can be commercialized, however regarding to the biologic medicines is not 
possible to reproduce precisely copies because the complexity of the protein 
macromolecules. This is the reason why biologic copies are not considerate generic 
copies but biosimilar ones.  An approved biosimilar is by definition highly similar to the 
reference drug such that any molecular or structural dissimilarities or potential differences 
in the underlying mechanisms do not affect the quality, efficacy and safety. A Biosimilar 
drug depends of the manufacture processing that includes: line cells, purification process, 
growth, storage, and transport conditions, so there’re always differences of glycosylation, 
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phosphorylation, sulfation and other post-translational modifications that can ultimately 
affect the drug efficacy and so have an impact regarding to immunogenicity. Is important 
to keep on mind that these differences are present not only between the reference drug 
and his biosimilar but also between different batches of the same reference or biosimilar 
biologic and product (Jahnsen, 2016; Park, Lee, Yun & Yoo, 2015).  
 How the development of a biosimilar does not need so many studies to clarify the 
quality, efficacy and safety, the cost of production is cheaper than a new biologic drug and 
for this reason attracts the interesting of countries governments because the changeability 
of a RMPs to biosimilars allows to reduce costs for the countries healthcare systems and 
consequently increase the accessibility of patients to these drugs. Although some 
concerns among physicians regarding to the quality, efficacy and safety are included in 
the equation and not only the financial aspect. The issues that have been emerging are if 
biosimilars have the same quality safety and efficacy, once perfect copies of some 
biologic agent are too difficult to reproduce. Other concern is if the changeability of a RMP 
by their biosimilar has impact on immunogenicity, and if so, if can have impact on efficacy 
and safety (Ben-Horin et al, 2015). 
 
1.6 How original mAbs and biosimilars have been compared 
The studies aimed to compare pharmacokinetic parameters such as maxim drug 
concentration at the ss (Cmax,ss); minimums drug concentration at ss (Cmin,ss); AUC at 
the ss (AUC,ss); time to reach Cmax (Tmax); the swing (Cmax,ss - Cmin,ss)/ Cmin,ss); 
degree of fluctuation (Cmax,ss - Cmin,ss)/average steady state plasma drug concentration 
(Cav,ss); mean residence time (MRT); terminal elimination half-life (T(1/2)); total body 
clearance at steady state (CI,ss); volume of distribution at ss (V,ss). Biosimilars also 
should show similar immunogenicity, comparatively with the RMP, by accessing the ADAs 
profile, that are generated to the therapeutic mAb influencing the pharmacokinetic (PK) by 
neutralizing and increasing the drug clearance. The blood drug levels and ADAs are 
detected with resource to immuno-assays (IAs) based on the linkage antigen-antibody 
(Park et al, 2013). Radioimmunoassay (RIA) and the enzymatic immunoassay (EIA) are 
two types of immune-assays widely described to detect serum drug levels and ADAs. RIA 
is a more sensitive assay then EIA, however it has the disadvantage to be a more 
complex technic which requires special laboratories prepared to the handling radioactivity 
and so, carrying more risks. Further, RIA assay is a more expensive technic then EIA. The 
enzymatic-linked immunosorbent assay (ELISA) is characterized to be simple to perform 
and cheaper comparatively to RIA. There are different types of ELISA such as direct 
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ELISA, indirect ELISA, sandwich ELISA competition ELISA and bridging ELISA (bELISA). 
The bELISA have been used for mAbs and ADAs detection, important parameters to 
monitoring patients, and to test the similarity between RMPs and biosimilars (Svenson, 
Geborek& Saxane, 2017). ADAs detection allows performing cross-react assays and 
neutralization assays. Cross react-react assays consists in verify if the ADAs generated 
by the patients that are under the original treatment recognize the biosimilar mAb, and to 
verify if the ADAs generated by patients treated with respective biosimilar recognize the 
original therapeutic mAb. When both situations happens is considerate that exists cross-
reactivity and it is a high indicative of similarity. The ability of the ADAs to neutralize the 
drug and affecting the effectiveness of the treatment is important to cooperate to test 
similarity in terms of effectiveness (Ben-Horin et al, 2015). 
Other way to evaluate ADAs is to study their response trough analyzing their 
biding sites. These technic consist in mapping the drug mAb to identify the regions where 
the epitopes are spotted. Mapping epitopes on the therapeutic mAb provide information 
about the regions of the drug that are more and the regions that are less immunogenic. 
Further, in the case that the epitopes are mostly placed at CDR regions, these data can 
be crossed with the results of the neutralization studies to verify if both studies are in 
agreement, once is expected that, if ADAs bind to CDRs region, also are neutralizing the 
drug activity that will not be able to link to their target. (Kosmač, Avčin & Toplak, 2011). 
 
1.7 Infliximab  
Infliximab (IFX) is a chimeric IgG1 mAb against soluble and transmembrane forms 
of tumor necrosis factor alpha (TNFα) containing about 25% murine Fv region and 75% 
human. IFX is able to bind TNFα an important pro-inflammatory cytokine. The biding of 
IFX to TNFα blocks the pro-inflammatory pathway decreasing inflammation. The class of 
mAbs which blocks TNFα is named as anti-TNFα agents. Anti-TNFα agents are indicated 
to treat chronic inflammatory diseases when patients stop responding to the conventional 
drugs (Lichtenstein, 2013).   IFX was produced in murine hybridoma cell lines (Sp2/0-
AG1) purchased from ATCC, Manassas, VA, USA) and commercialized with the brand 
name Remicade by Jassen Biotech and indicated as an anti-inflammatory medicine 
(Gabbani et al, 2017). Remicade is prescribed when the conventional treatments stop 
doing effect and is indicated to treat chronic inflammatory disease such as rheumatoid 
arthritis (RA) an immune condition which provokes inflammation of the joints, inflammatory 
bowel diseases (IBD) which includes crohn’s disease which cause inflammation of the 
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digestive tract associated with formation of fistulae, abnormal passageways between the 
gut and other organs.  IFX are also indicated to treat ankylosing spondylitis (AS), a 
disease which consists in inflammation and pain in the joints of the spine and finally 
psoriatic arthritis (PA) and psoriasis (PS). PA is characterized by emerging red scaly 
patches on the skin and also the inflammation of the joints while PS disease doesn’t 
includes inflammation of joints as a symptom.  Patients with IBD which the conventional 
drugs such as immunosuppressors or corticosteroids stops being effective’s starts doing 
biological treatments like IFX that allow patients achieve the remission state of respective 
chronic disease and then be prescribed as a maintenance dosage (EMA, 2018).   
  
1.8 Remicade dosage and routine of administration. 
Remicade was approved with a posology of intravenous (IV). The European Commission 
granted a marketing authorization valid throughout the European Union on 13 Aguste 
1999. It is administrated  by multiple intravenous infusions with the dosage of 3-5 mg/kg 
initially at week (w) 0, w2 and w6, with the propose to achieve a fast clinical improvement 
of symptoms and  after the week 6  is given  in intervals of 4-8 weeks  with dosage of 
3mg/kg for RA and 5mg/kg for the others indications based on several multicenter, 
randomized, double blind clinical trials for evaluation clinical efficacy and safety including 
IMPACT I, IMPACT II, ACCENT I, ACCENT II, ATTRACT, ASPIRE and START studies 
which established the optimal dosage and intervals of administration to get a better 
response and a minimum risk of adverse reactions or living treatment. (EMA, 2018); 
Gabbani et al, 2017). The dosage could be raised until 10mg/kg in patients who show a 
weak response. Remicade is administrated as an infusion lasting one-two hours and after 
the administration they are monitored for more one-two hours afterwards to prevent 
undesirable reactions especially situations of infusion-related reactions like anaphylactic 
shock that can endanger the patient's life and if so, it must be insured that the place where 
the drug administration is performed provides the necessary conditions to act in such a 
situation, so the administration of Remicade is limited to hospitals. How the patients under 
Remicade treatment needs to take multiple infusions to maintenance the disease in 
remission, the physician aim is to achieve the steady state by analyzing the IFX 
concentration contained in serum samples collected immediately before to the next 
Remicade infusion. So this serum samples are obtained when the IFX concentration are 
minimums and are designed as serum TL. When the serum TL shows the same value the 
physician can interpret that the patient achieved the steady state for IFX treatment. If 
some patient are keeping a maintenance dosage of IFX every 8 weeks and the actual 
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value of serum drug TL is higher than previous TL measurement, it can be interpreted by 
the clinic as an increased of the AUC and this indicate that the dosage of the present 
infusion should be lower or the dose interval of every 8 weeks reduced. By the other hand 
if the actual infliximab trough level (IFX-TL) value is minor then the previous measurement 
it suggests that the AUC decreased and due that the Remicade dosage should be incised 
or the infusions intervals expanded. The clinic can also consider that multiple Remicade 
infusions achieved Css when the AUC geometry is the same at the same interval of time 
that use to be as a standard interval of every 8 weeks. Farther the values of TL for every 8 
weeks, if was that the interval previously determined by the clinic for some patient under 
Remicade treatment, should be the same (Park et al, 2015). 
 
Table 1 – Representative scheme of the Infliximab infusion routine. 
 
IFX administration Week Month Year 
1
st
 w0  
- 
 
- 2
nd
 w2 
3
th
 w6 0 months + 1,5  
 
 
 
 
 
 
1 year 
4
th
 w14 2 months +1,5 
5
 th
 w22 4 months +1,5 
6
 th
 w30 6 months +1,5 
7
 th
 w38 8 months +1,5 
8
 th
 w46 10 months + 1,5 
9
 th
 w54 12 months +1,5 
10
 th
 w62 14 months +1,5  
 
 
 
 
 
2 years 
11
 th
 w70 16 months +1,5 
12
 th
 w78 18 months +1,5 
13
 th
 w86 20 months + 1,5 
14
 th
 w94 22 months +1,5 
15
 th
 w102 24 months +1,5 
 
The information contained on the table was adapted from Maini et al, 1999,Yoo et el, 2013. 
 
1.9 Biosimilar CT-P13 
CT-P13 is the IFX biosimilar approved in 2013 by EMA and is commercialized as 
Remsima in Europe and Inflectra in USA. The authorization to be commercialized as the 
IFX biosimilar to treat AS and RA conditions was given after CT-P13 shown comparable 
efficacy and safety in two pivotal studies. The PLANETAS with AS patients and the 
34 
 
PLANETRAS study with RA patients. Both studies published in 2013 shown comparable 
efficacy and safety among the AS and RA patients. These results obtained for AS and    
RA diseases, was considerable enough for EMA have extended the marketing 
authorization for IBD, PS and psoriatic arthritis PA. That extended step is called 
extrapolation. The extrapolation of data from some diseases to other diseases was 
criticized for different authors among the scientific community in 2014. The main concern 
was about if among patients with IBD the efficacy and the safety also are comparable for 
CT-P13 and original IFX (Casteele & Sandborn, 2015; Ha & Kornbluth, 2016; Hlavaty & 
Letkovsky, 2014). The results of CT-P13, in IBD, were obtained a bit later with post-
marketing records which suggesting similar effectiveness and safety comparing with 
original IFX (Farkas et al, 2017). Nowadays doubts related to the efficacy and safety of 
CT-P13 is not a concern anymore. However the concerns now remain regarding to the 
changeability of the RMP, the Remicade by the CT-P13 in patients that had started the 
Remicade treatment already. The issues are related to if changeability can affect 
immunogenicity and pharmacodynamics parameters of the patients that have been 
tolerated well Remicade. Despite documented studies have shown comparable efficacy 
and safety of CT-P13 and original IFX among the different diseases that are both 
indicated to treat, concerns tend to stay present among physicians (Fiorino et al, 2018). 
Immunogenicity is the most common mentioned concern mainly in patients which the 
reference product is changed by a biosimilar. Is a fact that biosimilar medication is 
susceptible to be immunogenic in some patients. The intensity of the immunogenicity 
among patients is variable because it depends of the immunologic features of each 
patient that always have differences. More over different biosimilars agents can present 
different immunogenicity standards so the comparison of immunogenicity levels between 
biosimilars and original drugs became a necessity by the importance of monitoring patient 
by the clinic to optimize the dosage route and minimize the risk of lack response to the 
treatment (Jahnsen, 2016). 
 
1.10 Therapeutic drug monitoring of IBD patients under IFX treatment 
The application of therapeutic drug monitoring (TDM) of patients who are being 
treated with IFX or CT-P13, provides an important tool for physicians enable a more 
effective and safe use of both medicine by their patients. TDM is consists in evaluating 
IFX and ADA serum TL by measuring serum TL levels. TDM is important because a better 
use of the medicine is related to a better quality of life improvement. TDM also helps 
physicians to identify the patients who will benefit and who don’t will benefit from 
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treatment and as well help physician to make decisions related increase or decrease 
dosage, changing infusions intervals or change the class of therapeutic mAb. The 
measurement of serum TL levels of patients been treated with IFX provide for different 
results possible (Bendtzen, Ainsworth, Steenholdt, Thomsen, & Brynskov, 2009,  
 
Table 2 – Representation of different possible results obtained by drug and ADA serum-TL 
measurement.  
 
Drug presence ADA presence Interpretation 
+ - 
The infliximab is being effective, and no immunogenicity detected. 
This result indicates that patient should keep continuing with 
treatment. 
 
- + 
No drug levels detected and positive result for ADAs presence. 
These results indicate that the ADAs presence are neutralizing 
IFX and increasing clearance. In that situation the patient should 
stop with IFX treatment and mAb switching is recommended once 
worse clinical outcomes are documented to be related this result. 
 
+ + 
Double positive result (DP) means that the ADAs that are being 
generated to the IFX are non-neutralizing ADAs and so don’t 
affect the PK. The treatment can be maintained if the 
effectiveness or safety doesn’t be compromised.  Is reported that 
ADAs detected in a double positive result can be transient and 
stop be detected in the future.  
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- - 
Double negative result (DN) is more difficult to interpret because 
there’s more than one situation that can be happen. One the one 
hand ADAs may be present and affecting PK by increasing the 
drug clearance; however these ADAs are not being detected at 
the ELISA assay because are forming complexes with IFX that for 
the same reason are not being detected as well. Is well 
documented the interference of the drug levels in the detection of 
ADAs because the complexes formed and is for that reason that 
the ADA detection should be performed with serum-TL because 
are collected at the Cmin. If patient are displaying high 
concentrations of IFX serum-TL could be the reason for the DN 
result and so the IFX treatment should be stopped. By the other 
hand if the patient is not generating ADAs the null levels of IFX 
can occur by other reasons that are provoking a fast clearance of 
IFX. Other factors such as high baseline C-reactive protein (CRP) 
levels, low albumin blood levels, high body site, sex (males have 
shown higher clearance then women). When null IFX trough 
levels are not related with ADAs the clinic decision should be 
increase the dosage or decrease dosage interval. 
 
Information based on Bendze et al, 2009; Khanna, Levesque, Sandborn & Feagan, 2014. 
 
1.11 The importance of the Therapeutic Drug Monitoring to evaluate efficacy and 
safety of CT-P13 and the original Infliximab. 
The therapeutic drug monitoring (TDM) is a useful tool to identify or prevent 
patients who will not respond to the treatment. The monitoring is achieved by studding TL 
serum concentrations of drug serum concentration and ADAs, obtained widely by bridging 
ELISA assay.  Loss of response (LoR) is associated with non-efficacy and non-safety of 
the drug, and these patients are more likely to develop LoR against the new drugs that will 
be administrated and more likely to have to do surgery. When the loss of respond 
happens in the beginning of treatment and the LoR are not associated with the presence 
of ADAs. This kind of LoR is called primary loss of response LoR. The patients which the 
treatment is efficient by a sustainable period of time and after achieved the remission 
phase starts developing ADAs that are responsible for LoR, that particular situation is 
named secondary LoR. Secondary LoR is a phenomenon that is associated with the 
development of neutralizing ADAs (NADAs) TDM is also useful to compare the 
immunogenic response to the drugs and so reference medicinal products (RMPs) can be 
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compared in terms of similarity with their biosimilars. That’s the reason why TDM is 
related with save costs with no impact on efficacy when helps to prove that the 
changeability by RMP to a biosimilar is feasible (Atzeni et al, 2013). With TDM the 
changeability by RMP to the similar can be tested and is designed as switching but also 
the switching of the bsimilar by the RMP can be tested and is called reverse switching. 
The change of one biosimilar for other biosimilar is named cross switching and TDM can 
contribute to test the similarity of the cross switching once new biosimilars should be 
launched in the market in the next years. Further TDM is a way to optimize serum drug 
levels and dose intervals, especially in patients with LoR (Michell et al, 2016). 
Secondary LoR are present in 40% of patients and also associated with low IFX-
TL. However secondary LoR are more difficult to determine when patients show double 
negative result. The bELISA used to detect IFX levels is also designed as double antigen 
ELISA because to detect anti-infliximab antibodies (AIAbs) the IFX is used as antigen 
where the ATIs recognize and link, and as well IFX is used to detect ATIs (Ungar et al, 
2015). The patients that present DN result with double antigen ELISA, 50% of these DN 
results are false negative DN, because in patients that the immunogenic response is a 
predominate mediated by monovalent IgG4 AIAbs, due the monovalent nature the IgG4 
are only able to establish one link to the IFX fixed on the ELISA bottom well, but can’t be 
detected by the labeled IFX used to detect AIAbs. This limitation of double antigen ELISA 
technic can be overcome by the anti-lambda ELISA assay. Anti-lambda ELISA assay use 
as a secondary Ab an anti-lambda able to detect IgG4 ATIs that contains light lambda 
chains. How IFX have kappa light chain, the secondary anti-lambda antibody doesn’t 
detect IFX and so is specific to detect IgG4 AIAbs. For patients that present DN result with 
double antigen ELISA assay and negative result for IgG4 AIAbs. detection, the low or null 
IFX levels should be considerate a cause of a non-immunogenic clearance. Monitoring 
IgG4 ADA profile is a way to distinguish between DN false negatives from DN positives 
and so helping physicians to choose the right decisions for the right patient. Evaluating 
DN results is a way to understand better how patients respond to the drug. And a better 
understanding of this subject can also be used to compare the immune response between 
RMP and biosimilar to test their similarity (Shapiro et al, 2011; Afonso et al, 2016). 
The extrapolation of the data obtained with CT-P13 with AS and RA patients, for 
IBD patients, was a concern in 2014 among the scientific community. The treatment with 
CT-P13 biosimilar, among IBD patients is nowadays known as feasible and safe (Blair & 
Deeks, 2016). Today the concern remains about if Remicade is more or less 
immunogenic than CT-P13 and so if the switch, cross switch and reverse switch are 
feasible among IBD patients without having impact in secondary LoR rates. The data 
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obtained here can also be compared with results obtained with different commercialized 
kits. That aspect is relevant once bridging ELISA assays have limitations and comparing 
the data obtained with different kits allows verifying if the different results are compatible. 
As well, rates of patients having secondary LoR due to the ADAs outcome can be 
compared not only between patients treated with the original and the biosimilar but with 
the rates obtained with other anti-TNF mAbs such as the humanized class of therapeutic 
mAbs because the controversy about who defends the implementation of switching of 
chimeric mAbs by humanized mAbs, arguing that humanized mAbs are likely less 
immunogenic then chimeric mAbs once they have less murine domains (Ilias, Gonzi, Kurti 
& Lakatos, 2018). 
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2 Aims 
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2.1 Overall goals and specific aims 
The authorization of biosimilar CT-P13 to treat patients with IBD was extrapolated 
from two pivotal studies performed with patients with RA and AS conditions, the 
PLANETRA and PLANETAS studies. The lack of published data about CT-P13 regarding 
to IBD patients in 2014 generated some concerns regarding similarity equivalency in IBD 
patients’ immune response.  
Nowadays the concern is not about the effectiveness and safety of CT-P13 in IBD 
but the switch, the reverse switch and inter-switch. Monitoring the therapeutic drug CT-
P13 has contributed to clarify these doubts, and to provide a more efficient use of the 
medicine among IBD patients. Thus helping physicians have better control over the 
patient’s PK and emerging ADAs responsible for secondary LoR. However, several 
essays still provide different sensibilities in drug and ADA detection, through which false 
negative results for ADA can occur. 
The lack of ADA detection associated to DN (IFX-/ADA-) result can be related to 
IFX-ADA complex formation, that the bELISA should not be able to detect, but also could 
be related with a limitation of bELISA to detect monovalent IgG4 ADA subtypes.  
           The results obtained with the therapeutic drug monitoring are important to be 
compared with the ones obtained with Remicade for a better understand about the 
similarity of both medicines. 
The identification of ADAs epitopes can be relevant once it can provide information 
about which infliximab regions are more immunogenic, suggesting the presence of 
immunodominant epitopes which can be relevant to the development of anti-
immunogenicity medicines. Further, mapping assay is a way to compare the immune 
response intensity of CT-P13 and Remicade, and so testing if both drugs offer 
comparable safety in terms of immunogenicity. 
The immunogenicity can have more impact on the effectiveness when the ADAs 
generated are directed to CDR regions because that blocks the interaction of infliximab 
with TNFa. NADAs which have such ability are responsible for a highest LoR. Due that is 
important to compare the ability of biosimilar and Remicade to induce the formation of 
NADAs with propose of evaluating the efficacy and safety. 
            The aim of this study is to evaluate the similarity of the biosimilar CT-P13 with the 
original Infliximab, the Remicade drug, among IBD patients aiming to know if the 
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changeability of the Remicade for the biosimilar CT-P13 can be implemented successfully 
in patients with IBD and so providing a cheaper treatment. 
 
To achieve these goals four tasks were established: 
 Task 1: Measure CT-P13 and ADAs TL-serum levels to verify how immunogenicity 
affects the CT-P13 pharmacokinetic of IBD patients.   
 
 Task2: Mapping the epitopes of ADAs directed to the biosimilar and epitopes of 
ADAs directed to Remicade to verify if the immune response of IBD patients 
treated with CT-P13, is similar to IBD patients under the original Remicade. 
 
 Task3: Mapping the epitopes of IgG4 ADAs subtypes, directed to the biosimilar 
and epitopes of IgG4 ADAs directed to Remicade to verify if the immune response 
of IBD patients treated with CT-P13, is similar to IBD patients under the original 
Remicade. 
 
 Task4: Comparison of the similarity between a biosimilar and original product 
regarding the intensity of the immunogenicity and perform a neutralizing essay to 
detect the presence of NADAs among IBD patients treated with CT-P13 and 
Remsima. 
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3 Methods 
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All assays and laboratory procedures here described in this chapter were 
optimized and systematically revised in order to minimize inter and intra-assay variability. 
 
3.1 Patients and healthy controls 
Patients and healthy controls are evidenced in the Table 3. 
Table 3 - Patients and health controls. 
 
Number of 
Volunteers 
Source and type of samples 
1 Healty control (Naïve to the Inflammatory Bowel Disease) 
90 
Blood samples of patients with Inflammatory Bowel Disease treated with CT-
13 a IFX biosimilar, from Santa Maria Hospital, Lisbon, Portugal; Hospital 
Destrital da Figuira da Foz, Figueira da Foz, Portugal; Hospital Nossa Senhora 
do Rosário, Barreiro, Portugal belonging to FFUL biobank. 
45 
Serum samples of patients with Inflammatory Bowel Disease treated with CT-
P13 from Ireland biobank. 
3 
Serum samples of patients with Inflammatory Bowel Disease treated with CT-
P13 from Cyprus biobank. 
12 
Positive serum samples of patients with Inflammatory Bowel Disease treated 
with Remicade® from a German biobank and containing anti-drug antibodies 
in the serum.  
34 
Already tested, ten ADA negative serum samples were used to achieve the 
cut-off of the in-house ELISAs assay for epitope mapping.   
O.D. cut-off value = 0,101. The O.D. values until 1.01 would be consider as 
negative for ADA presence. 
 
Blood samples from patients with Inflammatory Bowel Disease and healthy 
subjects were collected and serum was isolated and stored at -20º C. until analysis. 
 
3.2 Immunogenic response of IBD patients to the IFX biosimilar CT-P13 drug based 
on IFX and ADA TL-serum profile. 
The identification of positive serum samples, from the IBD patients under the 
biosimilar Remsima, containing the ADAs to the biosimilar CT-P13, was detected by a 
commercial kit (Theradiag LISA-TRACKER Duo Infliximab, France).The commercial kit 
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can measure two parameters, the Infliximab and the anti-Infliximab ADAs levels. IFX drug 
is detected based an indirect ELISA and ADAs by bringing ELISA model (Appendix 8.1).  
3.3 Infliximab synthetic peptides 
Based on literature ADAbs bind preferentially on the murine portions of the IFX 
drug spotted in the Fab fragments of IFX drug. To map the epitopes of ADAbs on IFX 
mlecule, 21 peptides of the IFX Fab fragment were commercially synthetized 
(ProteoGenix; Bachem). These 21 peptides were previous identified by phage display 
technology for being potential epitopes where the anti-Infliximab antibodies (AIAbs) 
attach. Here it was intended to verify which infliximab peptides are epitopes of the anti-
Remicade and anti-Biosimilar (CT-P13) ADAs. The reactivity between the peptides, which 
mimics potential epitopes and the ADAs of positive serum samples suggest 
immunogenicity and so the intensity of the immunogenic response to the biosimilar and 
original IFX can be evaluated. The assay as well allows verifying to understand the 
regions of the IFX molecule that are more immunogenic for the anti-Remicade ADAs and 
for anti-biosimilar ADAs. 
The IFX peptides amino acid sequences are evidenced in Table 4 and their 
localization on the IFX molecule are represented on Figure 5, Figure 6 and Figure 7. 
Table 4 – Infliximab commercialized synthetized peptides 
 
IFX peptides  Amino acid resides  
IFX 1  YCQQSHSWPFTFGSG 
IFX 2 QFVGSSIHWYQQRTN 
IFX 3 NHWMNWVRQSPEKGL 
IFX 4 EDTGVYYCSRNYYGS 
IFX 5 NAKTKPREEQYNSTY 
IFX 6 MSGIPSRFSGSGSGT 
IFX 7 WMNWVRQSPEKGLEW 
IFX 8 SRDDSKSAVYLQMTD 
IFX 9 YCSRNYYGSTYDYWG 
IFX 10 YQQRTNGSPRRTNGS 
IFX 11 SINTVESEDIADYYC 
IFX 12 (AS) ATHYAESVKGRFTIS 
IFX 13 (LA) LEWVAEIRSKSINSA 
IFX 14 (LY) LQMTDLRTEDTGVYY 
IFX 15 (LE) LLTQSPAILSVSPGE 
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IFX 16 (PV) PGERVSFSCRASQFV 
IFX 17 (SG) SPRLLIKYASESMSG 
IFX 18 (SN) SSSLGTQTYICNVHN 
IFX 19 (KV) KDTLMISRTPEVTCV 
IFX 20 (ST) SGSGSGTDFTLSINT 
IFX 21 (GF) GGSMKLSCVASGFIF 
 
  
 
Figure 5 -  Localization of the infliximab synthetized peptides on chain H FAB IFX 
In yellow is represented the sequence of the variable heavy chain (VH) and in grey the constant heavy chain 1 
(CH1). The red words represent the sequence of IFX which the synthetized peptides (IFX3, IFX4, IFX7, IFX8, 
IFX9, IFX12, IFX13, IFX14, IFX18, IFX21) are located. 
Source: Chain H, Crystal Structure Of Tnf-alpha In Complex With Infliximab Fab – Protein - NCBI. (2016). 
Ncbi.nlm.nih.gov. Retrieved 29 October 2016, from https://www.ncbi.nlm.nih.gov/protein/471270577. 
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Figure 6 - Localization of the infliximab synthesized peptides on chain L FAB IFX. 
In yellow is represented the sequence of the variable light chain (VL) and in grey the constant heavy chain 1 
(CH1). The red words represent the sequence of IFX which the synthetized peptides (IFX1, IFX2, IFX6, IFX10, 
IFX11, IFX15, IFX16, IFX17, IFX20) are located. 
Source: Chain L, Crystal Structure Of Tnf-alpha In Complex With Infliximab Fab - Protein - NCBI. (2016). 
Ncbi.nlm.nih.gov. Retrieved 29 October 2016, from https://www.ncbi.nlm.nih.gov/protein/471270576. 
 
Figure 7 - Localization of the synthetized peptides on the FC IFX 
In grey is represented the sequence of the constant heavy chain 2 (CH2) and in black the constant heavy 
chain 3 (CH3). The white words represent the sequence of IFX which the synthetized peptides (IFX19, IFX5) 
are located.  
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Source: IgG [Homo sapiens] - Protein - NCBI. (2016). Ncbi.nlm.nih.gov. Retrieved 29 October 2016, from 
https://www.ncbi.nlm.nih.gov/protein/185362. 
Lyophilized peptides were diluted in PBS 1x to a final concentration of 1mg/mL and 
stored at -80Cº away from light according with the guideline of peptides solutions provided 
by the peptides supplier. 
 
3.4 Development of two in house ELISA assays to screen which the synthetic 
peptides bind to ordinary IgGs ADAs and IgG4 ADAs, contained in the positive 
serum samples from the IBD patients under the biosimilar treatment and the IBD 
patients under the original IFX treatment. 
An ELISA assay was developed to screen which synthetic peptides bind to the 
ADAs contained in the serum of patients with Inflammatory IBD, developing 
immunogenicity. The ELISA optimization process included testing different peptides 
concentrations, sample dilutions, coating, blocking and washing buffers, conjugated 
antibody as evidenced in Table 5: 
Table 5 – ELISA assay optimization 
 
ELISA step Optimization 
Samples 
PBST 0.1% 
PBS 1X 
Blocking Buffer 
PBS 1X containing 1% bovine serum albumin 
PBS 1X containing 3% bovine serum albumin 
PBS 1X containing 5% bovine serum albumin 
PBS 1X containing 1% Caseine 
PBS 1X containing 3% Caseine 
PBS 1X containing 5% Caseine 
PBS 1X containing 1% Pierce 
PBS 1X containing 3% Pierce 
PBS 1X containing 5% Pierce 
Washing Buffer 
PBS 1X 
PBS 1X containing 0.05% Tween 20 
Anti-Human IgG Horseradish 
Peroxidase (HRP) Antibody 
 
Dilution: 1:5000 / 1:25000 
PBS 1X containing 1% bovine serum albumin  
Anti-Lambda IgG-HRP 
Antibody 
Dilution: 1.5000 / 1.10000 / 1:20000 / 1:30000 
PBS 1X containing 1% bovine serum albumin 
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Anti-human IgG4 biotinylated 
Antibody 
Conjugated with: Streptavidin 
                            Anti-mouse IgG Antibody (Dilution:            
1:1000 / 1:5000/ 1:10000)      
Dilution: 1:5000 / 1:10000 / 1:20000  
PBS 1X containing 1% bovine serum albumin 
 
 
3.5 Screening epitopes of the anti-Infliximab (anti-Remicade and anti-biosimilar) IgG 
antibodies 
An ELISA assay was developed to identify which infliximab peptides are 
recognized by the anti-Remicade antibodies (ARAbs) and anti-biosimilar IgGs antibodies 
(ABAbs) from the IBD patients that developed immunogenicity against the respective IFX 
drug. 
Two 96-wells plates (Nunc Immobilizer Amino Plates; Thermo Scientific) for the 
anti-Remicade IgG antibodies detection and another two for the anti-biosimilar IgG 
antibodies were coated with 100µg/µL synthetized infliximab peptides (ProteoGenix; 
Bachem) diluted in sodium carbonate (Na2Co3 0,1M pH9.6) overnight (ON) at 4ºC. The 
96-wells plates were coated with each IFX peptide according to the scheme represented 
in Figure 8. 
Figure 8 – Scheme of the IFX peptides coated on 96-wells plates and the indication how serum 
samples was added.  
Each well of each line is coated with a different peptide and for each line of the 96-plates is added a sample 
from only one patient, so for each serum sample from just one patient is added the same amount of serum for 
each one of the 21 peptides coated at the same line. 
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The Blocking buffer (PBST 1x containing 5% bovine serum albumin) was 
subsequently added and incubated for 1hour at 37ºC. After that the blocking buffer was 
discarded and the wash step performed with PBST (PBS 1x containing 0,1% Tween 20) 
five times in every wells.  The serum samples from IBD’s patients with immunogenicity, so 
samples that contains the anti-Infliximab antibodies was diluted 1:9 and the sample of the 
negative controls (IBD`s patients that have no immunogenicity so, their serum samples 
have no anti-Infliximab antibodies) was diluted 1:9 as well and 50µL of each already 
prepared serum samples and also the control sample was added to the respective 96-
plate line wherein to test each already prepared serum sample for all 21 peptides more 
the negative peptide control (IFX C), how is represented in the scheme above. The 
incubation of the serum samples was done for 1hour at 4ºC. Then, the plates containing 
was discarded and another wash step was performed 5x with PBST. Subsequently was 
added 50µL of anti-lambda-HRP antibody (Abcam) diluted 1:5000 in PBST 1x in 1% of 
bovine serum albumin. The choice of the anti-lambda-HRP antibody to detect the 
presence of AIAbs was because they link to the IgGs which have lambda-chain and how 
infliximab molecule has Kappa-chain is not recognized by the anti-lambda-HRP antibody, 
and so that this makes that antibody specific to detect the anti-Infliximab antibodies. This 
antibody is also conjugated to a peroxidase enzyme (HRP). The micro plates after the 
addiction of 50µL per well of the secondary antibody the anti-lambda-HRP was incubated 
at 4ºC for 1hour. The wells content was discarded and after that one last wash step 5x 
with PBST was done before the addiction of 50µL of the subtract (3,3’5,5’ 
tetramethylbenzidin; Theradiag), incubated for about 15-20 minutes in the dark at 4ºC until 
the addiction of 50µL of sulfuric acid (H2SO4 0,25M) to block the enzymatic reaction. After 
this process the wells that contains the presence of anti-Infliximab antibodies became 
yellow and the yellow color intensity is directly proportional regarding how higher is the 
presence of the anti-Infliximab antibodies for each well. Then the optical density (OD) was 
read in a spectrophotometer at 450 nm within 30 minutes after stopping reaction   
The chosen of the anti-lambda-HRP Ab as a secondary antibody instead a 
biotinylated IFX like in the commercialized kit was made because biotinylated IFX needs 
the streptavidin-HRP conjugated to allow the enzymatic reaction happen and we observed 
in our controls an unspecific reaction between the streptavidin and some ones of the IFX 
peptides as a false positive result. The reason because the unspecific reaction just 
happened with some IFX peptides and not with the complete IFX molecule could be 
because the lack of folding, so peptides have linear shape and this can favor unspecific 
reactions. The new strategy was to use the anti-lambda-HRP Ab as a secondary Ab 
because it is able to recognize the lambda chains of the AIAbs and how IFX molecule has 
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kappa chains instead lambda, makes anti-lambda-HRP Ab specific to detect the presence 
of AIAbs on this ELISA assay. The utility of the anti-lambda ELISA in ADA detection was 
described by Kopylov et al, 2011 and is here represented in the Figure 9. 
 
 
 
 
 
 
 
 
Figure 9 - Detection of anti-infliximab IgG antibodies 
ELISA assay scheme of ant-infliximab IgG antibodies detection by anti-lambda secondary antibody. How is 
represented in this figure, the wells are coated with the respective infliximab peptides (IFX peptide). The anti-
infliximab antibodies (AIAb) containing in the sample of IBD patients treated with an infliximab drug, a 
reference medical product (RMP) or a biosimilar CT-P13, they link to the IFX peptide when it is recognized as 
an epitope. Anti-lambda secondary antibody (anti-lambda-HRP Ab) conjugated with a horseradish Peroxidase 
enzyme (HRP) binds to the lambda chain of AIAb but is not able to binds to the IFX peptides because IFX has 
a chain kappa instead lambda.  TMB (3,3’5,5’ tetramethylbenzidine) is the subtract of the enzymatic reaction 
of HRP, so the enzymatic reaction is proportional to the amount of AIAb present on serum from IBD patients. 
Source: Adapted from Kopylov et al, 2011. 
 
3.7 Screening of Infliximab epitopes of the anti-Infliximab (anti-Remicade and anti-
biosimilar) IgG4 antibodies 
Was developed an ELISA assay to identify which ones of the infliximab peptides 
were recognized by the anti-Remicade and anti-biosimilar IgG4 antibodies from patients 
with IBD that developed immunogenicity to the respective infliximab drug. 
Two 96-wells plates (Nunc Immobilizer Amino Plates; Thermo Scientific) for the 
anti-Remicade IgG4 antibodies detection and another two for the anti-biosimilar IgG4 
antibodies, were coated with 100µg/µL synthetized IFX peptides (ProteoGenix; Bachem) 
diluted in sodium carbonate (Na2Co3 0,1M pH9.6) O.N. at 4ºC. N. 96-wells plates were 
coated with each IFX peptide according to the scheme represented above on Figure 9. 
TMB 
 
 
Anti-lambda-HRP Ab 
 
AIAb 
 
IFX peptide 
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The Blocking buffer (PBST 1x containing 3% casein) was subsequently added and 
incubated for 1hour at 37ºC. After that the blocking buffer was discarded and the wash 
step performed with PBST (PBS 1x containing 0,1% Tween 20) five times for each well.  
The serum samples from the IBD patients  with immunogenicity, so samples that contains 
the anti-Infliximab IgG4 antibodies was diluted 1:9 and the sample of the negative control 
(IBD patient that have no immunogenicity, so his serum samples have no anti-Infliximab 
antibodies) was diluted 1:9 as well and 50µL of each already prepared serum samples 
and also the control sample was added to the respective 96-plate line wherein to test each 
already prepared serum sample for all 21 peptides more the negative peptide control (IFX 
C). The incubation of the serum samples was done for 1hour at 4ºC. Then, the plates 
containing was discarded and another wash step was performed 5x with PBST. 
Subsequently was added 50µL of anti-Human biotinylated IgG4 Ab (Life Technologies) 
diluted 1:5000 in PBST 1x in 1% of bovine serum albumin and the incubation was for 
1hour at 4ºC. The choice of the anti-Human biotinylated lgG4 Ab to detect the presence of 
anti-Infliximab IgG4 antibodies, was because it binds specifically to the IgG4 and how 
Infliximab is an IgG1 this secondary antibody is only able to bind to the anti-Infliximab 
IgG4 on this ELISA. Other aspect is that this secondary biotinylated antibody binds to the 
streptavidin conjugate because of the link between biotin and streptavidin. The 
streptavidin conjugated (LISA-TRACKER Duo Infliximab, Threadiag) consist in a 
streptavidin linked to a peroxidase enzyme (HRP). For this step was supposed the 
addition of 50µL of streptavidin conjugate however once again because the nonspecific 
reaction between the streptavidin conjugate and some ones of the Infliximab peptides, the 
methodology strategy for this currently step was changed. So, addition of streptavidin 
conjugate was changed for the addition of 50µL of mouse-antibody-HRP (CalbioChem) 
diluted 1:1000 (mouse-antibody-HRP diluted in PBST containing 1% of bovine serum 
albumin). This “3th antibody” is murine and recognize human fragments, so is expected 
that it recognizes the anti-Infliximab antibodies but not the infliximab peptides since these 
peptides belongs to the murine fragments of Infliximab drug. The micro plates were 
incubated 1hour at 4ºC, after the addiction of the 3th antibody. After that one last wash 
step 5x with PBST was done before the addiction of 50µL of the subtract TMB (3,3’5,5’ 
tetramethylbenzidin; Theradiag), incubated for about 15-20 minutes in the dark at 4ºC until 
the addiction of 50µL of sulfuric acid (H2SO4 0,25M) to block the enzymatic reaction. After 
of this process the wells containing the presence of anti-Infliximab antibodies became 
yellow and the yellow color intensity is directly proportional regarding how higher is the 
presence of the anti-Infliximab antibodies for each well. Then the optical density (OD) was 
read in a spectrophotometer at 450 nm within 30 minutes after stopping reaction. This 
ELISA assay is represented on Figure 9. 
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Figure 10 - Detection of anti-infliximab IgG4 antibodies 
ELISA assay scheme of anti-infliximab IgG4 antibodies detection by anti-Human IgG4 secondary antibody. 
How is represented in this figure, the wells are coated with the respective infliximab peptides (IFX peptide). 
The IgG4 antibodies (IgG4-AIAb) containing in the sample of IBD patients treated with an infliximab drug, a 
reference medical product (RMP) or a biosimilar CT-P13, link to the IFX peptide when it is recognized as an 
epitope. The anti-human IgG4 secondary antibody (anti-human IgG4 Ab) recognize the IgG4-AIAbs from IBD 
patient’s serum but not the murine Fab IFX peptides even the IFX5 and IFX19 peptides that are human was 
previous tested and any bind was observed. For the detection of anti-human IgG4 Ab that is a murine Ab, the 
detection was performed with a anti mouse antibody conjugated with a horseradish peroxidase enzyme (HRP) 
(anti-mouse-Ab-HRP).  TMB (3,3’5,5’ tetramethylbenzidine) is the subtract of the enzymatic reaction of HRP, 
so the enzymatic reaction is proportional to the amount of IgG4-AIAbs present in the serum from IBD patients. 
 
3.8 Identification of neutralizing anti-infliximab profile 
The goal at this task was to verify which serum samples, from patients with IBD 
with immunogenicity against infliximab, have anti-infliximab antibodies able to neutralize 
the Infliximab drug. To perform this was tested 7 positive serum samples from patients 
treated with Remicade and so with anti-Remicade antibodies and 7 serum positive 
samples from patients treated with the biosimilar Remsima so their serum contains anti-
Remsima antibodies. To evaluate if positive serums are able or not to neutralize the 
respective drug, firstly was red the amount of drug for every 14 serum samples with 
resource to the marketed ELISA kit (LISA-TRACKER Duo Infliximab, Threadiag) and 
every serum samples were previously prepared diluted to 1/201. From this dilution was 
used 100µL per well to perform the assay. The same marketed ELISA kit was used at the 
neutralization assay but before that each 7 serum samples containing the anti-Remicade 
antibodies were diluted 1/101 (100µL of PBST 1x containing 10µL of positive serum) each 
one in a microtube and then was added 100 µL of Remicade with a concentration of 
1,5µg/mL. After that each serum sample contained in each microtube became diluted as 
1/201. The same procedure was done for the seven serum samples containing the anti-
TMB 
Anti-mouse-Ab-HRP 
 
Anti-human IgG4 Ab 
 
IgG4-AIAb 
IFX-peptide 
 
 
53 
 
Remsima antibodies and the only exception was instead the addition of Remicade was 
added 100µL of Remsima with a concentration of 1,44µg/mL. All 14 microtubes containing 
the serum together with the respective infliximab drug, was left on ice for 1 hour. 
Furthermore, the negative controls were also prepared. Remicade negative control (100µL 
of Remicade in a concentration of 1,5µg/mL diluted in 100µL of PBST) and Remsima 
negative control without any serum added (100µL of Remsima in a concentration of 
1,44µg/mL diluted in 100µL of PBST). Finally was performed the commercialized ELISA 
kit (LISA-TRACKER Duo Infliximab, Threadiag) to verify each serum samples neutralized 
the infliximab drug. Finally, a serum will be considering a neutralizing serum if the result of 
the neutralizing assay will be minor then the sum of the infliximab amount already present 
in the serum plus the result of the negative control.  
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4 Results 
 
 
 
 
 
55 
 
Patients whose serum presented (IFX>4,196 μg/mL) and presented IFX levels 
(ADA>36,692 ng/mL) were considered positive according with the standard curve 
performed, following the kit instructions. The commercial kit provided 4 possible results.  
 A Positive result for Immunogenicity occur when ADAs where found high 
and low or negative presence of IFX levels.  
 A negative result for immunogenicity happens when no or low ADA 
presence and high IFX-TL levels is detected. 
 Double positive (DP) result is considerate when IFX and ADA profile are 
high at the assay. 
 Double negative (DN) if both parameters are low or undetectable. 
 
Table 6 – ELISA Results of the drug and ADA serum-TL found in among the IBD patients. 
 
IFX ADA Patients % 
+ - 31 52.5% 
- + 11 18.6% 
+ + 6 10.17% 
- - 11 18.6% 
 
52.5% of the patients included in this study shown high IFX TL-serum levels and 
low ADAs detected. 18.6% of patients had low or null IFX TL-serum levels detected. The 
The value of DP was 10.17% and 18.6% for DN result. 
 
4.1 Screening of anti-Remicade IgG epitopes 
IBD patients with immunogenicity against Remicade drug do not develop anti-
Remicade IgGs to a specific spot on the infliximab molecule. The anti-Remicade IgGs can 
be randomly generated to different places on the Fab portion of infliximab depending of 
the individual response of each patient to the drug. 
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Figure 11 - Optical Density values of seropositive patients which them serum contains the anti-
Remicade antibodies against Remicade.  
Red points represent the OD values of the positive serum containing the ARAb for each of the 21 IFX 
peptides. It is considered as an epitope OD values above of the standard deviation of the respective IFX 
peptide. OD cut-off value = 0,101. 
 
4.2 Screening of anti-biosimilar IgG epitopes 
IBD patients with immunogenicity against the biosimilar CT-P13 drug do not 
develop anti-biosimilar IgGs to a specific site on the infliximab molecule as well. Anti-
biosimilar IgGs are randomly generated to different sites on the Fab portion of infliximab 
according to the individual response of each patient to the biosimilar drug (Figure 12). 
 
Figure 12 - Optical Density values of seropositive patients which them serum contains the anti-
biosimilar antibodies against biosimilar drug.  
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Green points represent the OD values of the positive serum containing the ABAb for each of the 21 IFX 
peptides. It is considered as an epitope OD values above of the standard deviation of the respective IFX 
peptide. OD cut-off value = 0,101. 
 
4.3 Screening of anti-Remicade IgG4 epitopes 
IBD patients with immunogenicity against Remicade drug have titers of anti-
Remicade IgG4 antibodies. These antibodies are randomly generated by individual 
patients to different epitopes spotted on the infliximab Fab portion, so are not specific to a 
dominate region on the Remicade infliximab drug (Figure13). 
Figure 13 - Optical Density values of seropositive patients which them serum contains the anti-
Remicade IgG4 antibodies against Remicade. 
The orange dots represent the OD values of the positive serum containing the IgG4-ARAb for each of the 21 
IFX peptide Cut-off value = 0,15s. It is considered as an epitope OD values above of the standard deviation of 
the respective IFX peptide. OD cut-off value = 0,101. 
 
4.4 Screening of anti-biosimilar IgG4 antibodies 
IBD patients with immunogenicity against biosimilar CT-P13 drug have titers of 
anti-biosimilar IgG4 antibodies. These antibodies are randomly generated by individual 
patients to different epitopes spotted on the infliximab Fab portion, so are not specific to a 
dominate region on the biosimilar infliximab molecule. Serum samples with OD values 
above standard deviations of each peptide were considered positives. 
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Figure 14 - Optical Density values of seropositive patients which them serum contains the anti-
biosimilar IgG4 antibodies against biosimilar. 
Green points represent the OD values of the positive serum containing the IgG4-ABAb for each of the 21 IFX 
peptides. It is considered as an epitope OD values above of the standard deviation of the respective IFX 
peptide. OD cut-off value = 0,101 
Figure 15 – Average of the mapping ELISA assay to detect IgG ADA subtype epitopes 
In the graph is described the averages of the ODs values corresponding to the reaction of the synthetic 
peptides with the IgG ADAs of the IBD patients treated with the biosimilar CT-P13 and patients treated with 
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the original  Remicade drug. The differences wasn’t statistically significant for the major of the peptides tested 
however only for IFX9 peptide the difference was statically significant (P<0.05). OD cut-off value = 0,101. 
Related information in appendix 2. 
 
Figure 16 – Average of the mapping ELISA assay to detect the IgG4 ADA subtype epitopes 
In the graph is described the averages of the OD values corresponding to the reaction of the synthetic 
peptides with the IgG4 ADAs of IBD patients treated with the biosimilar CT-P13 and  Remicade. The 
differences wasn’t statistically significant for the major of the peptides tested however only for IFX15, IFX16, 
IFX21 was no statically significant (P<0.05). OD cut-off value = 0,101. Related information in appendix 2. 
 
4.5 Identification of neutralizing anti-Remicade antibodies profile  
In the Table 7 are the results of the blank (0,066) and the negative control minus 
the blank OD value (0,202). This value represents the amount of Remicade detected 
without any incubation with serum of IBD patients containing ARAbs. In the Table 8 we 
can observed that any Remicade amount was detected for the seven serum form patients 
with IBD treated with Remicade and with presence of ADA. 
The OD results of the neutralizing assay are evidenced in the Table 9 and 
comparing with the result of the negative control (0,202) only the serum of the patient 3 
(Figure16) neutralized the amount of Remicade from 0,202 to 0,017. It is important to 
realize that, except the serum sample of patient 3, all the ODs values of Remicade 
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incubated with the others 6 serum samples are higher than the single Remicade without 
any serum added. 
 
Table 7 – OD values of negative controls and the white. 
 
 
Table 8 – OD values of IFX measured on IBD patients with Immunogenicity 
 
 
Table 9 – OD values of IFX measured after the neutralizing assay. 
 
Blank O.D.  (PBST without serum) 0,066 
Negative Control O.D. (Remicade diluted in PBST 1/ 2, no serum added) 0,268 
Negative Control O.D. less blank O.D (0,268 - 0,066) 0,202 
100µL of patient’s serum (P) incubated        1 
hour with 100 µL of Remicade (R)  
(Serum samples in a final dilution of 1/201) 
O.D. of Neutralizing ELISA Assay minus 
White (0,066) 
Patient 1 serum sample (P1) incubated with R 0,296 - 0,066 = 0,230 
Patient 2 serum sample (P2) incubated with R 0,318 - 0,066 = 0,252 
Patient 3 serum sample (P3) incubated with R 0,251 - 0,066 = 0,185 
Patient 4 serum sample (P4) incubated with R 0,269 - 0,066 = 0,203 
Patient 5 serum sample (P5) incubated with R 0,284 - 0,066 = 0,218 
Patient 6 serum sample (P6) incubated with R 0,281 - 0,066 = 0,215 
Patient 7 serum sample (P7) incubated with R 0,345 - 0,066 = 0,279 
Patients (P) serum samples O.D. 
Serum diluted in PBST 1/201 
Patients O.D. – White O.D. (0.066) 
Patient 1 serum sample (P1) 0,063 - 0,066 = - 0,003 
Patient 2 serum sample (P2) 0,063 - 0,066 = - 0,003 
Patient 3 serum sample (P3) 0,058 - 0,066 = - 0,003 
Patient 4 serum sample (P4) 0,052 - 0,066 = - 0,003 
Patient 5 serum sample (P5) 0,058 - 0,066 = - 0,003 
Patient 6 serum sample (P6) 0,058 - 0,066 = - 0,003 
Patient 7 serum sample (P7) 0,053 - 0,066 = - 0,003 
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Figure 17 - Optical Density values of Remicade detected in ELISA assay after the neutralizing process 
with positive serum to anti-Remicade antibodies. 
Is consider as a neutralizing serum when the red bars are lower than the blue bars. Red bars represent the 
OD measures of Remicade IFX amount after incubated 1 hour with the respective patient`s sera (P1, P2, P3, 
P4, P5, P6, P7) with IBD treated with Remicade IFX and which their serum contains the ARAbs. The blue bars 
represent the OD value of the biosimilar amount after incubated 1 hour with PBS instead a positive serum for 
ARAbs, so the blue bars represent the negative controls. There are no green bars in this figure like in the 
Figure 15 because green bars represent the OD values of the amount of IFX drug detected in the serum 
samples of the patients before (P1, P2, P3, P4, P5, P6, P7) before the incubation with the Remicade for 1 
hour. As any Remicade amounts were detected in the serum samples before the addition of Remicade to the 
serum for the neutralizing assay, there are no green bars in this figure.  
 
4.6 Identification of neutralizing anti-biosimilar antibodies serum profile 
The Table 10 shows the results of the blank value (0,066) and the negative control 
after discounted the blank OD value (0,008) that represent the amount of Remicade 
detected without incubation with serum from IBD patients containing ABAbs. In the Table 
11 is the OD values detected for each of the seven serum samples serum form patients 
with IBD treated with the IFX biosimilar and which their serum contains the ABAbs. 
The OD values of the neutralizing assay evidenced in Table 12, comparing with 
the OD value of the negative control (0,008) plus the OD value of the biosimilar amount 
detected on patient`s serum are demonstrated in the Figure17 which can be observed that 
the serum of the patient 7 neutralized all the amount of the biosimilar from 0,008 to 0,007 
which we considered as 0,00 that means a decrease of the amount of 100%.    
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Table 10 – OD values of negative controls and the white. 
 
Table 11 – OD values of Biosimilar measured on IBD patients with Immunogenicity 
 
Patients (P) serum samples O.D. 
Serum diluted in PBST 1/201 
Patients O.D. minus white O.D. (0.066) 
Patient 1 serum sample (P1) 0,072 - 0,066 = 0,006 
Patient 2 serum sample (P2) 0,061 - 0,066 = - 0,005 
Patient 3 serum sample (P3) 0,091 - 0,066 = 0,025 
Patient 4 serum sample (P4) 0,053 - 0,066 = - 0,013 
Patient 5 serum sample (P5) 0,074 - 0,066 = 0,008 
Patient 6 serum sample (P6) 0,072 - 0,066 = 0,006 
Patient 7 serum sample (P7) 0,059 -  0,066 = - 0,007 
 
Table 12 –  OD values of IFX measured after the neutralizing assay 
 
100µL of patient’s serum (P) incubated        1 
hour with 100 µL of biosimilar CT-P13 (B) 
(Serum samples in a final dilution of 1/201) 
O.D. of Neutralizing ELISA Assay minus 
White (0,066) 
Patient 1 serum sample (P1) incubated with B 0,089 - 0,066 = 0,023 
Patient 2 serum sample (P2) incubated with B 0,074 - 0,066 = 0,008 
Patient 3 serum sample (P3) incubated with B 0,106 - 0,066 = 0,04 
Patient 4 serum sample (P4) incubated with B 0,087 - 0,066 = 0,021 
Patient 5 serum sample (P5) incubated with B 0,084 - 0,066 = 0,018 
Patient 6 serum sample (P6) incubated with B 0,08 - 0,066 = 0,014 
Patient 7 serum sample (P7) incubated with B 0,061 - 0,066 = - 0,005 
White O.D.  (PBST without serum) 0,066 
Negative Control O.D. (CT-P13 diluted in PBST 1/ 2, no serum added) 0,074 
Negative Control O.D. minus white O.D (0,074 - 0,066) 0,008 
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Figure 18 -  Optical Density values of the biosimilar detected on ELISA assay after the neutralizing 
process with positive serum to the anti-Remicade antibodies 
Is consider as a neutralizing serum when the red bars are lower than the blue bars plus green bars. Red bars 
represent the OD measures of the biosimilar IFX amount after incubated 1 hour with the respective patient`s 
sera (P1, P2, P3, P4, P5, P6, P7) with IBD treated with biosimilar IFX and which their serum contains the 
ABAbs. The blue bars represent the OD value of the biosimilar amount after incubated 1 hour with PBS 
instead a positive serum for ABAbs, so the blue bars represent the negative controls. The green bars is the 
OD values of the biosimilar amount already contained in the serum of the patients (P1, P2, P3, P4, P5, P6, 
P7) before the incubation with the biosimilar for 1 hour. 
 
No different capacity to induce emerging NADAs in IBD patients was reveled since 
the differences are statistically insignificant (p=0,304), P>0,05. 
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5 Discussion 
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The expiration of the patent of Remicade opened the possibility for other 
companies to commercialize IFX biosimilars (Ghosh, 2013). CT-P13 was the first IFX 
biosimilar introduced in the market and the authorization to go to market given by EMA 
was achieved based on two pivotal studies, the PLANERA and PLANETRAS. These 
proved similar effectiveness and safety among RA and AS patients (Park et al, 2013; Yoo 
et al, 2013) based on the data CT-P13 got the approval to treat patients with IBD by EMA. 
The extrapolation of the data from one condition to another was considered a concern 
among some physicians (Casteele & Sandborn, 2015). The concerns about extrapolation 
emerged in 2014, because of lack of long term experience with the use of biosimilar CT-
P13 in IBD treatment (Hlavaty, & Letkovsky, 2014). The argument against extrapolation 
was regarding to differences in the immune response of patients induced by both drugs 
since it is difficult to reproduce an identical copy of a biologic mAbs and structural 
differences may be present (de Mora & Fauser, 2017). However, studies have been made 
with IBD patients treated with CT-13 and the effectiveness and safety have been 
compared with the original Remicade based on drug and ADA TL-serum profile. To 
access these two parameters several commercialized ELISA kits, such as LISA-
TRACKER® ELISA kit (Theradiag, Marne La Vallee, France, or Alpha Laboratories, 
Heriot, UK), Promonitor® ELISA kit (Proteomika, Progenika Biopharma, Bizkaia, Spain) or 
Prometheus TNF-α-Blocker ELISA kit (Immundiagnostik AG, Bensheim, Germany) have 
been used however different detection sensibilities are reported, although the differences 
aren’t significant (Afonso et el 2017). Furthermore, some authors have also reported 
limitations of these kits specifically regarding with the ADA detection in the presence of 
drug levels (Afonso et el 2016).  It’s documented that formation of immune complexes 
(IFX-ADA is associated with poor ADA detection on bELISA assays leading to DN (IFX-/-
ADA) results (Ungar et al, 2015).  
The results obtained in this study revealed an inverse relation between CT-P13 
levels and ADA in 71% of the TL-serum samples, showing that in the majority of the 
samples ADA presence affects the PK. These results are in agreement with previous 
studies (Farkas et al, 2017; Afonso et el 2017) in IBD. In this study we also verified 18.6% 
for both, DP and DN results. The DP result, presented in some patients, could be 
explained by the presence of low affinity and non-neutralizing ADAs. On the other hand, 
the percentage of DN results is lower than results obtained in other studies. DN results 
have been associated with a lower intensity of immunogenicity and it’s predictive of ADAs 
outcome in the future. Some studies also described that the DN is more susceptible to 
assay variability by which the low or null ADA concentration can be a false negative result 
It’s hypothesized that DN can be related with a high monovalent IgG4 ADAs presence, 
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that after complexing IFX, due to their monovalent characteristic, is not able to be 
detected by a bELISA (Ungar et al, 2015, Bendtzen et al, 2009).  
It is documented that the monovalent IgG4 subtype is a transitory form that tends 
to form dimers consisting in bivalent IgG4 form (Kolfschoten et al, 2007) which reinforces 
the idea of the DN, and is predictive of the subsequently ADA emerging in patients. These 
results were accessed by Theradiag Kit. A study has been done that verified that this kit is 
less sensitive in ADA detection comparatively with other ELISA, although the differences 
weren’t significant. In some samples which were verified DN results with Theradiag Kit, 
showed ADA presence when the assay was performed with other commercialized kits 
(Afonso et el 2017). 
In the mapping essay ADA epitopes was accessed by using an in house anti-
lambda essay (Kopylov et al, 2011). In the process of this ELISA optimization an 
unspecific reaction between the synthetic peptide and streptavidin-HPR conjugated was 
detected. In order to solve this problem the biotinylated IFX used to detect ADA in bELISA 
was switched by an anti-lambda-HRP secondary antibody. The mapping essay shows that 
the generated ADAs of the different patients don’t react homogeneously with the synthetic 
peptides. Which reinforce the idea that the ADAs generated are polyclonal. Observing the 
tendency lines of CT-P13 and Remicade we verified that they have a very similar profile 
regarding to the averages of the different 21 peptides tested. The essay of IgGs ADAs 
epitopes mapping we can observe that are regions more immunogenic than others. We 
can observe two peaks between the IFX4 and IFX7 peptides and other peak between 
IFX13 and IFX18 peptides. The screening of IgG4 ADAs epitopes, the tendency line of the 
averages obtained with the sample containing anti-biosimilar IgG4 ADAs was higher than 
the tendency line of anti-Remicade IgG4 ADAs, although the difference is not very 
significant, however anti-biosimilar ADAs react strongly between IFX13-IFX18 peptides. 
This peak wasn’t so evident for anti-Remicade ADAs. This data suggests that the 
biosimilar is lightly more immunogenic than Remicade. However this results should be 
carefully evaluated because IgG4 subtypes are just a small percentage of ADAs that are 
in their majority IgG1 subtype (Vultaggio et al, 2018). Furthermore, IgG4 ADA subtypes 
have been associated with lack of ADA detection and DN as well (Ungar et al, 2015). 
Looking at the tendencies obtained with ADA IgGs in general, we can’t deny that this 
points to a high similarity between these drugs. The limitations of the epitope mapping 
using synthetic peptides have already been previously highlighted. The linear nature of 
synthetic peptides can expose some domains able to react and specifically resulting in a 
false positive result (Kosmač, et al, 2011). It can be the reason why the majority of the 
peptides reacted non-specifically with streptavidin-HRP conjugated and the same it’s not 
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observed with the entire IFX molecule. This sustained the idea that the lack of fold is 
responsible for false positive results. Ideally epitope mapping essays performed with non-
linear peptides are able to mimic the fold of IFX molecule, since this technology is already 
available (Timmerman, 2007). This can better clarify the presence of immune-dominant 
epitopes and avoid risk of false positives and be considerated as positives.  
NADAs have been associated to a sever LoR once this kind of ADAs are directed 
to the IFX CDR regions blocking the interaction with TNFa (Atzeni et al, 2013). NADAs 
profile has been used to compare the similarity of biosimilar and original. In this study, in 
the neutralizing assay was also verified similarity between Remicade and biosimilar 
results. In the serum sample of the patients treated with Remicade and containing positive 
ADAs against Remicade only 14% reveal the presence of NADAs and 86% don’t. Once all 
the TL-serum samples were previously tested for the amount of IFX levels and every 
sample revealed very low or null IFX levels, we hypothesized that the presence of a 
NADAs is not a determinant factor for IFX clearance. However the data here presented 
are not in agreement with the results found in PLANETRA and PLANETAS studies 
patients (Park et al, 2013; Yoo et al, 2013), where the percentage of samples non-
containing NADAs was highest despite of the presence of NADAs was similar for both in 
the patients treated with biosimilar and Remicade. 
In general we can claim based on our data that the biosimilar and original 
Remicade evoke similar immunogenic response among IBD patients. Further this results 
corroborates with the cross react studies (Reinisch, 2017), which also revealed 
comparable similarity between both medicines. Nowadays the extrapolation is not a 
concern anymore but physicians are more concerned with changeability that includes the 
switching, reverse-switching, inter-switching and the changeability for other anti-TNFa 
agent such Adalimumab (Ilias, Gonczi, Kurti & Lakatos, 2018). Seems clear based in all 
data already published that the changeability is feasible and safe. Although concerns can 
rise related to the prescription order, for example which medicine should be prescribed 
firstly, a full humanized or a chimeric mAb in order to reduce the probability of secondary 
LoR event. With the launch of new biosimilars the same concerns that were directed to 
CT-P13 will be directed to the new emergent drugs. Based on the results here obtained 
and the results already published mainly the cross-react results it seems obvious that 
changeability of original mAb by a biosimilar or a biosimilar for other biosimilar is not a 
concern anymore, since the same concern should be applied to the new batches of the 
same biologic drug, because small structural differences between different batches are 
documented (Schiest et al, 2011). The nature of immunogenicity seems to be much more 
dependent of each patient than the medicine. 
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Finally, the appearance of biosimilars such as CT-P13 seems to be positive since it 
consists out of new tools to treat IBD. Secondary LoR to TNFa agents is a natural feature 
of the patients that make the changeability inevitable, and so, with more anti-TNFa agents 
available, the remission can be maintained for a longer period of time reducing the 
necessity to change the treatment with anti-TNFa by other biologic class or reducing the 
necessity of surgery. 
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6 Conclusion 
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Responding to the established goals, we obtained 4 different results using the 
commercial kit (LISA-TRACKER Duo infliximab Theradiag, France). We verified an 
inverse proportion between CT-P13 and ADAs in 71% of IBD patients which suggest that 
ADAs presence affected CT-P13 PK. 37% of IBD patients present high drug levels. 6% 
present DP (+IFX/+ADA) result and 11% presented DN (-IFX /-ADA) result. 
The mapping essay detected the epitopes of positive ADAs shows that CT-P13 
and Remicade cause similar immunogenicity among IBD patients.  
The similarity of both drugs was not so evident regarding the epitopes mapping of 
IgG4 ADAs subtypes. 
Finally we detected neutralizing ADAs in 14% of the serum samples containing the 
anti-biosimilar ADAs and 14% of the samples containing anti-Remicade antibodies 
suggesting comparable immunogenicity. However the results obtained in this task should 
be observed carefully once the number of positive serum samples was shortened. 
In general we can conclude based on our results that the biosimilar CT-13 and the 
original Remicade are comparable in immune response among patients with IBD, and so 
switching, reverse-switching and changeability should be not a subject of concern among 
the physicians.  
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8.1 Scheme of LISA Duo Infliximab TRACKER® ELISA kits (Theradiag, France) 
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8.2 Averages of anti-Remicade and anti-Biosimilar 
Average of anti-Remicade and anti-Biosimilar ADAs  
 
 
Average of anti-Remicade and anti-Biosimilar IgG4 ADAs  
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